Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other p
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading provider ... today announced that it will hold an investor conference ... financial results for the first quarter of fiscal 2015 ... the current fiscal year. , The dial-in number for ... 2014, at 5 p.m. EDT (2 p.m. PDT) is ...
(Date:7/31/2014)... 2014  Smith & Nephew (LSE:SN, NYSE: ... today announced its entry into the forefoot market ... Repair System. Comprised of three separate repair options, ... ligament repair and reconstruction, a metatarsal osteotomy guide, ... (PIP) fusion, also known as hammer toe correction. ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... The global market for molecular diagnostics ... according to a new study by Grand View Research, ... the subsequent introduction of advanced cancer diagnostic technologies are ... the next six years. Moreover, the growing global base ... coupled with disease triggering lifestyle habits such as smoking ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5
... potentially reach $1 billion by 2014SEATTLE, March 19 ... and MTA: CTIC) reviewed CTI,s programs in a presentation ... Wednesday, March 18th . Mr. Philips, highlights focused ... non-Hodgkin,s lymphoma (NHL) and OPAXIO for treatment of non-small ...
... (Nasdaq: MEDX ) announced today that it is ... Today & Tomorrow Conference at 11:20 a.m. Eastern Time on ... and will be available in the Investor Relations section of ... of the presentation will be available following the event. About ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced ... (R7227) and the company,s research programs related to the hepatitis ... 44th Annual Meeting of the European Association for the Study ... The abstracts are expected to be available at ...
Cached Biology Technology:Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 2Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 3InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 2InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 3
(Date:7/30/2014)... reversible epigenetic processes to regulate its genes, and adapt ... picture of the genome regulation taking place in the ... Genome Biology and illustrates how the truffle deals ... The authors say this may shed light on how ... truffles (Tuber melanosporum), also known as Prigord truffles, have ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
(Date:7/30/2014)... of the Entomological Society of America (ESA) has elected ... election as a Fellow acknowledges outstanding contributions to entomology ... extension, or administration. The following Fellows will be recognized ... which will be held November 16-19, 2014 in Portland, ... a professor with the Department of Plant, Soil and ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2Entomological Society of America recognizes 2014 fellows 2Entomological Society of America recognizes 2014 fellows 3Entomological Society of America recognizes 2014 fellows 4Entomological Society of America recognizes 2014 fellows 5Entomological Society of America recognizes 2014 fellows 6Entomological Society of America recognizes 2014 fellows 7Entomological Society of America recognizes 2014 fellows 8Entomological Society of America recognizes 2014 fellows 9Entomological Society of America recognizes 2014 fellows 10Entomological Society of America recognizes 2014 fellows 11Entomological Society of America recognizes 2014 fellows 12Entomological Society of America recognizes 2014 fellows 13Entomological Society of America recognizes 2014 fellows 14Entomological Society of America recognizes 2014 fellows 15Entomological Society of America recognizes 2014 fellows 16Entomological Society of America recognizes 2014 fellows 17
... antibodies for use in vaccines and cancer medicines, enzymes ... substances can already be produced on a large scale ... met by making use of living cells or organisms. ... the target protein to bacteria, yeasts, or cultures of ...
... hosting a conference for researchers and clinicians on depression, ... Treatment Battlefeld and New Research," on Friday, November 1, ... Icahn School of Medicine at Mount Sinai, The Bonnie ... and 102nd Streets) in New York City. Recent meta-analyses ...
... electricity is hard to come by and scientific instruments are ... medical lab is rarely an option. Scientists are now reporting ... void with no electronics required. Their study on the extremely ... of time, appears in the ACS journal Analytical Chemistry ...
Cached Biology News:Biomolecules for the production line 2Biomolecules for the production line 3Towards a real understanding of depression 2